Salinomycin inhibits hepatocellular carcinoma cell invasion and migration through JNK/JunD pathway-mediated MMP9 expression

LING XU, TING WANG, WEN-YING MENG, JUE WEI, JIA-LI MA, MIN SHI and YU-GANG WANG

Department of Gastroenterology, Shanghai Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China

Received October 8, 2014; Accepted November 28, 2014

DOI: 10.3892/or.2014.3680

Abstract. The antibiotic salinomycin (Salin) was recently identified as an antitumor drug for the treatment of several types of solid tumors. However, the effects of Salin on the migratory and invasive properties of hepatocellular carcinoma (HCC) cells are unclear. The present study aimed to determine the antitumor efficacy and mechanism of Salin in HCC cells. Human HCC cells (HCCLM3) treated with Salin showed a concentration-dependent reduction in cell migration and invasion, and this was associated with reduced MMP9 expression. The MMP9 promoter and enhancer in a luciferase reporter assay revealed that Salin can regulate MMP9 expression through an activator protein (AP-1) site within the MMP9 enhancer. JunD, one of the AP-1 components, was significantly decreased by Salin in a concentration- and time-dependent manner. Salin was able to induce c-Jun NH2-kinase (JNK) phosphorylation and to block both JunD and MMP9 expression. Our results showed that JNK phosphorylation and JunD may be involved in the Salin-regulated MMP9 signaling pathway in HCCLM3 cells and may mediate HCC cell biological characteristics. Our studies provide new insight into the antitumor effects of Salin.

Introduction

Hepatocellular carcinoma (HCC) is a major health issue and has one of the highest mortality rates in the world (1). Unfortunately, most cases of HCC are often diagnosed at an advanced stage and are not suitable for curative treatments such as resection, transplantation (2,3), radiofrequency ablation, transarterial chemoembolization (TACE), or targeting drugs such as sorafenib (4,5). It is known that tumorigenesis is a multi-stage complex process involving multiple genes. Activation of resistant genes or the mutation of sensitive genes in the development of cancer may lead to the failure of chemotherapeutic agents. Therefore, the study of anticancer drugs is currently a hot research topic.

Salinomycin (Salin) has been widely used in animal husbandry for many years worldwide. Salin is a polyether antibiotic used to kill gram-positive bacteria including mycobacteria and parasites such as Plasmodium falciparum. In addition, Salin, as an ionophore with strict selectivity for alkali ions, exhibits a wide range of biological activities, including inhibition of adipogenesis and anti-allergic activity (6,7). Recent studies indicate that Salin has antitumor effects, with attenuation of proliferation, autophagy and cell death/apoptosis in human cancer cells or cancer stem cells (8-11). However, the effects of Salin on the migratory and invasive properties of HCC cells, and the underlying molecular mechanisms remain obscure.

In the present study, we demonstrated that the anti-invasive and anti-migratory effects of Salin are mediated by downregulation of MMP9 through the JNK/JunD pathway leading to inhibition of HCC cell invasion and metastasis.

Materials and methods

Cell lines and culture conditions. The human HCC cell lines with highly invasive capacities (HCCLM3 and MHCC-97H) were obtained from the Chinese Academy of Sciences Type Culture Collection cell bank. The cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Ann Arbor, MI, USA) supplemented with 10% fetal bovine serum (FBS; Life Technologies) and both penicillin and streptomycin (100 mg/ml each) at 37˚C in a humidified atmosphere of 5% CO₂.

Cell migration and invasion assays. Cells (5x10⁴) were seeded in the upper chamber of Transwell plates with 8-μm pores (Costar, Cambridge, MA, USA). The lower chambers of the Transwell plates were filled with 500 μl medium containing 10% FBS as a chemoattractant. The plates were incubated at 37˚C for 12 h. Cell invasion assays were performed using the
same method. The Transwell chambers were covered with 50 µl 1:2 Matrigel and phosphate-buffered Saline mixture, and the cells were cultivated for 24 h. Cells that migrated or invaded to the lower surface were stained with Giemsa solution and quantified by counting five randomly selected microscopic fields at x200 magnification.

**Angiogenesis assay.** The supernatant was collected from the HCCLM3 cells cultured in a serum-free medium with or without Salin treatment. The Matrigel angiogenesis assay was performed as previously described (12,13). In brief, BD Matrigel (BD Biosciences San Jose, CA, USA) matrix was plated in 96-well flat-bottom cell culture cluster plates. After incubation for 30 min, 10,000 HUVEC cells/well and 50 µl of the HCCLM3 supernatant with or without Salin treatment were placed on the Matrigel. The plate was incubated at 37°C for 16-18 h. Following incubation, the wells were photographed, and the results were quantified by measuring the length of the tube-like structures using Nikon NIS-Elements computer software.

**Enzyme-linked immunosorbent assays (ELISA).** To measure the concentrations of MMP2 and MMP9 secreted from the cultured tumor cell lines, the supernatants were assessed using ELISA. Cells (5x10^4/well) in 24-well plates were incubated at 37°C in a 5% CO₂ atmosphere in serum-free DMEM containing 10% FBS. After 24 h, the cells were washed and incubated for 24 h in serum-free medium with or without Salin (5-20 µmol/l). The culture-conditioned medium was collected, centrifuged, and the concentrations of MMP2 and MMP9 were determined by quantitative ELISA (R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions.

**MMP9 promoter and enhancer and luciferase reporter gene constructs.** To clone the putative promoter and/or enhancer region of the MMP9 gene, a PCR-based method was used, and specific primers were designed from the 5’-end of the known MMP9 promoter sequence from a previous study (14). The amplified DNA fragment of 2302 bp was cloned into the pGL3-Basic vector (Promega, Madison, WI, USA) to construct pGL3-MMP9-WT containing the potential enhancer element. AP-1 site-mutated MMP9 (pGL3-MMP9-mAP1-1, pGL3-MMP9-mAP1-2 and pGL3-MMP9-mAP1-1+2), NF-κB site-mutated MMP9 and Sp-1 site-mutated MMP9 (pGL3-MMP9-mSp1) luciferase promoters were used in the transient transfection assays as previously described (15,16). These vectors contain the luciferase gene driven by the SV40 promoter. The composition of the constructs was confirmed by restriction endonuclease digestion and DNA sequencing.

**Transfection and luciferase reporter assays.** Cells (5x10^4/well) in 24-well plates were incubated at 37°C in a 5% CO₂ atmosphere in serum-free DMEM. After 24 h, the plasmids were transfected into cells using Lipofectamine-2000 reagent according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). After transfection, the cells were cultured...
in FBS without or with Salin (5-20 µmol/l) for 24 h. The cell lysate was used to detect luciferase activity according to the manufacturer’s protocol (Promega). Luciferase activity was normalized to the β-galactosidase activity in the cell lysates and expressed as the average of three independent experiments.

Western blotting. Total cellular proteins were extracted using RIPA buffer and quantified by the BCA method. The sample proteins were separated by electrophoresis on SDS-PAGE and transferred onto a PVDF membrane. After blocking, the membranes were incubated overnight at 4°C with various primary antibodies and α-tubulin at 1:500-1:1000 dilution (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The secondary HRP-conjugated antibodies were diluted 1:2000. The immunocomplexes were detected using the ECL system (Beyotime Biotechnology, China). A Li-COR Odyssey scanner (LICOR) was used to detect the antigens on the blots.

Statistical analysis. All statistical analyses were performed using SPSS 17.0 software. Data are reported as mean ± SD, and mean values were compared using the Student’s t-test and ANOVA. Values of p<0.05 and p<0.01 were considered statistically significant.

Results

Salinomycin inhibits HCC cell migration and invasion. It is known that Salin has anticancer activity, and previous studies...
XU et al.: ANTICANCER MECHANISMS OF SALINOMYCIN IN HEPATOCELULAR CARCINOMA CELLS

have shown that it can induce cell apoptosis and suppress cancer cell proliferation. We determined the effects of Salin on the migration and invasion of HCC cells using the Transwell assay and tube formation assay. Salin (5-20 µmol/l) significantly inhibited HCCLM3 cell migration and invasion in a concentration-dependent manner (Fig. 1A). In addition, significantly fewer integrated capillary-like structures were found in the HCCLM3 cells treated without or with Salin (5-20 µmol/l). The results revealed that the AP-1 site is critical for Salin-regulated MMP9 enhancer activity. (B) Western blot analysis indicated that the expression of the components of AP-1 (JunB and JunD) was regulated by Salin (5-20 µmol/l). *p<0.05 vs. the control, **p<0.01 vs. the control. These results are representative of three independent experiments.

Figure 3. Salin inhibits MMP9 expression by decreasing JunD and AP-1 activation. (A) The regulation of Salin on the MMP9 promoter and enhancer. Relative luciferase activities of pGL3-MMP9-WT (containing the potential enhancer element) and several mutant derivatives of the MMP9 enhancer region for all motifs (pGL3-MMP9-mNF-xB, pGL3-MMP9-mSp1, pGL3-MMP9-mAP1-1, pGL3-MMP9-mAP1-2 and pGL3-MMP9-mAP1-1+2) were transfected in HCCLM3 cells treated without or with Salin (5-20 µmol/l). The results revealed that the AP-1 site is critical for Salin-regulated MMP9 enhancer activity. (B) Western blot analysis indicated that the expression of the components of AP-1 (JunB and JunD) was regulated by Salin (5-20 µmol/l). *p<0.05 vs. the control, **p<0.01 vs. the control. These results are representative of three independent experiments.

Suppression of cancer cell invasion and metastasis by Salin is associated with the downregulation of MMP9. To elucidate the anti-invasive and anti-migratory mechanisms of Salin, we examined MMP9 and MMP2 expression. HCCLM3 cells were treated with Salin at concentrations of 5-20 µmol/l. The results showed that Salin at 5 µmol/l or higher concentrations attenuated MMP9 expression in the HCCLM3 cells, but did not significantly affect the expression of MMP2 (Fig. 2A). In addition, Salin inhibited MMP9 expression at the protein level in a concentration-dependent and time-dependent manner (Fig. 2B). To determine the importance of MMP9 in the anti-invasive effect of Salin in HCCLM3 cells, we established stable overexpression of MMP9 in the HCCLM3 transfectants by infecting the cells with a lentivirus encoding MMP9. The results showed that overexpression of MMP9 was significantly blocked by 10-39% in the Salin-treated group compared with the group without Salin treatment (p<0.01; Fig. 2C). The results also showed that Salin decreased MMP9

Figure 3. Salin inhibits MMP9 expression by decreasing JunD and AP-1 activation. (A) The regulation of Salin on the MMP9 promoter and enhancer. Relative luciferase activities of pGL3-MMP9-WT (containing the potential enhancer element) and several mutant derivatives of the MMP9 enhancer region for all motifs (pGL3-MMP9-mNF-xB, pGL3-MMP9-mSp1, pGL3-MMP9-mAP1-1, pGL3-MMP9-mAP1-2 and pGL3-MMP9-mAP1-1+2) were transfected in HCCLM3 cells treated without or with Salin (5-20 µmol/l). The results revealed that the AP-1 site is critical for Salin-regulated MMP9 enhancer activity. (B) Western blot analysis indicated that the expression of the components of AP-1 (JunB and JunD) was regulated by Salin (5-20 µmol/l). *p<0.05 vs. the control, **p<0.01 vs. the control. These results are representative of three independent experiments.
expression by 14-36% compared with the random group (Ver transfectants) (p<0.05; Fig. 2C). These results suggest that MMP9 may play a role in the anti-invasive and anti-migratory effects of Salin.

The AP-1 site within the MMP9 enhancer is essential for Salin-regulated MMP9 activity. The MMP9 promoter contains two AP-1 sites (located at -79 bp and -533 bp), a Sp1 site (located at -560 bp) and an NF-κB site (located at -600 bp). To determine whether regulation of MMP9 is related to these cis-acting regulatory elements for transcription factors, several constructs with deletions or mutations were used and have been described in Materials and methods. Experimental cells were transfected with reporter vectors that included the tandem repeat of AP-1, NF-κB or Sp-1 binding sites. Noteworthy, luciferase activity in the cells with the AP-1 construct was significantly reduced by treatment with Salin at 10-20 µmol/l, whereas luciferase activity containing the NF-κB or Sp-1 binding site construct showed no statistically significant changes in the cells treated with Salin (Fig. 3A). These results showed that both AP-1 sites in the MMP9 promoter were essential for Salin-regulated MMP9 enhancer region activity.

Figure 4. JNK/JunD signaling pathway is involved in MMP9 downregulation by Salin. (A) Salin-regulated JunD and MMP9 expression. Western blotting showed that Salin inhibited JunD and MMP9 expression induced by anisomycin, a JNK activator. (B) Western blotting revealed that JunD and MMP9 expression was inhibited by Salin at the indicated times (0, 0.5, 1, 3, 6, 12 and 24 h) during incubation. (C) The effects of Salin on JNK activation at the indicated time periods (0.5, 3, 12 and 24 h). After treatment without or with 20 µmol/l Salin, JNK1, JNK2, p-JNK1 and p-JNK2 were examined by western blotting with JNK and phosphor-JNK specific antibodies. The ratio of p-JNK1/JNK1 and p-JNK2/JNK2 showed that JNK phosphorylation was regulated by Salin. (D) The hypothetical mechanism by which Salin causes MMP9 inhibition and related signaling events in the presence of its anti-invasive and anti-migratory effects. *p<0.05 vs. the control, **p<0.01 vs. the control. Data are representative of at least three independent experiments.
**Discussion**

Salinomycin (Salin) is crucially involved in the regulation of cell proliferation, growth and survival, in addition to antitumorigenesis. However, the role of Salin in cancer invasion and metastasis is not well understood. In the present study, we confirmed that Salin inhibited HCC cell migration and invasion in vivo through the downregulation of MMP9 rather than MMP2. In addition, our results indicated that Salin regulated MMP9 at the protein level in a concentration-dependent and time-dependent manner.

It is well known that degradation of the extracellular matrix is the angiogenic switch in tumorigenesis. In particular, MMP9, its enhancer and promotor can bind to the transcription factors AP-1, Spl and NF-κB, and can be affected by a variety of signals (16). Several natural products or chemicals play a role in antitumor activity by interfering with MMP9 gene expression. For example, hesperidin obstructs the activity of MMP9 by inhibiting NF-κB (17), and genistein suppresses MMP9 transcription by inhibiting AP-1 and NF-κB activity (18). In the present study, we showed, for the first time, that Salin acts through AP-1 to inhibit MMP9 expression. Previous evidence indicated that the regulation of JunD expression diverges from the well-characterized growth factor-inducible pattern of the c-Jun early response genes and AP-1 autoregulation (19,20). Furthermore, we found that the onco-suppressive effects of Salin may partially mediate MMP9 expression via the JNK/JunD pathway, causing the suppression of cancer cell invasion and migration (Fig. 4D). These results suggest that Salin inhibits cancer-cell invasion by decreasing JNK/JunD signaling and AP-1 activation to prevent MMP9 expression.

In conclusion, we discovered novel pathways associated with the ability of Salin to suppress tumorigenesis. The onco-suppressive effects of Salin may be partially mediated via JNK/JunD-regulated MMP9 expression. These findings confirm the possibility that Salin may be a potential anticancer drug targeting MMP9.

**Acknowledgements**

This study was funded by the Shanghai Municipal Health Bureau Key Disciplines Grant (no. ZK2012A05), the Shanghai Municipal Health Bureau (no. 20134100), the Natural Science Foundation of the Science and Technology Commission of Shanghai Municipality (no. 14ZR1431600).

**References**

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Belghiti J and Fuks D: Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer 1: 71-82, 2012.
3. Fan ST: Hepatocellular carcinoma - resection or transplant? Nat Rev Gastroenterol Hepatol 9: 732-737, 2012.
4. Raza A and Sood GK: Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 20: 4115-4127, 2014.
5. Feng K and Ma KS: Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 20: 5987-5998, 2014.
6. Szkudlarek-Mikho M, Saunders RA, Yap SF, Ngeow YF and Chin KV: Salinomycin, a polyether ionophoric antibiotic, inhibits adipogenesis. Biochem Biophys Res Commun 428: 487-493, 2012.
7. García-Domenech R, Zanni R, Galvez-Llompart M and de Julián-Ortiz JV: Modeling anti-allergic natural compounds by molecular topology. Comb Chem High Throughput Screen 16: 628-635, 2013.
8. Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, Wang CF, Lu J, Zhou YQ, Xu XF, Xu L and Guo CY: Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One 7: e50638, 2012.
9. Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, Lu J, Yang J, Zhu R, Zhang H, Zhou Y, Xu L and Guo C: The synergistic in vitro and in vivo effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS One 9: e97414, 2014.
10. Al Dihaier Y, Attoub S, Arafat K, Abouqamar S, Eid A, Al Faresi N and Iratni R: Salinomycin induces apoptosis and senescence in breast cancer: upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochim Biophys Acta 1830: 3121-3135, 2013.
11. Yue W, Hamaï A, Tonelli G, Bauvy C, Nicolas V, Tharinger H, Codogno P and Mehrpour M: Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy 9: 714-729, 2013.
12. Yesildal F, Aydin F, Deveci S, Tekin S, Aydin I, Mammodov R, Pereratini O, Avcu F, Ariciel C and Ozgurtas T: Aspartame induces angiogenesis in vitro and in vivo models. Hum Exp Toxicol pii: 0960327114537535, Jun 12, 2014 (Epub ahead of print).
13. Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding ZB, Devbhondari RP, Huang XY, Qiu SJ, Shi YH, Dai Z, Yang XR, Yang GH and Fan J: CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 52: 183-196, 2010.
14. Raney BJ, Cline MS, Rosenbloom KR, Dreszer TR, Learned K, Barber GP, Meyer LR, Sloan CA, Malladi VS, Roskin KM, Suh BB, Hinrichs AS, Clawson H, Zweig AS, Kirkup V, Fujita PA, Rhead B, Smith KE, Pohl A, Kuhn KM, Karolchik D, Haussler D and Kent WJ: ENCODE whole-genome data in the UCSC genome browser. Nucleic Acids Res 39 (Database issue): D871-D875, 2011.

15. Chuang TW, Lee YC and Kim CH: Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 18: 1123-1125, 2004.

16. Hong S, Park KK, Magae J, Ando K, Lee TS, Kwon TK, Kwak JY, Kim CH and Chang YC: Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells. J Biol Chem 280: 25202-25209, 2005.

17. Yeh MH, Kao ST, Hung CM, Liu CJ, Lee KH and Yeh CC: Hesperidin inhibited acetaldehyde-induced matrix metalloproteinase-9 gene expression in human hepatocellular carcinoma cells. Toxicol Lett 184: 204-210, 2009.

18. Wang SD, Chen BC, Kao ST, Liu CJ and Yeh CC: Genistein inhibits tumor invasion by suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. BMC Complement Altern Med 14: 26, 2014.

19. Hernandez JM, Floyd DH, Weilbaecher KN, Green PL and Boris-Lawrie K: Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 27: 4757-4767, 2008.

20. Chen HW, Lee JY, Huang JY, Wang CC, Chen WJ, Su SF, Huang CW, Ho CC, Chen JJ, Tsai MF, Yu SL and Yang PC: Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res 68: 7428-7438, 2008.